Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I

Neoplasma

Volumn 52, Issue 2, 2005, Pages 159-164

  Mego, M ^a   Ebringer, L ^b   Drgona L ^a   Mardiak, J ^a   Trupl, J ^a   Greksak, R ^a   Nemova, I ^a   Oravcova, E ^a   Zajac, V ^c   Koza, I ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Febrile neutropenia; Infection prevention; Probiotics; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; DISULFOTON; ENTEROCOCCUS FAECIUM M 74; PROBIOTIC AGENT; SELENIUM; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSLOCATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; FEBRILE NEUTROPENIA; FEMALE; GERM CELL TUMOR; HUMAN; INTESTINE MUCOSA; LACTIC ACID BACTERIUM; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL;

EID: 20144388695     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. BABA E, NAGAISHI M, FUKATA T, ARAKAWA A. The role of intestinal microflora on the prevention of Salmonella colonization in gnotobiotic chickens. Poultry Sci 1991; 70: 1902-1907.
2. BATT RM, RUTGERS HC, SANCAK AA. Enteric bacteria: friend or foe? J Small Anim Pract 1996; 37: 261-267.
3. BORN P, LERSCH C, ZIMMERHACKL B, CLASSEN M. The Saccharomyces boulardii therapy of HIV-associated diarrhoea (letter). Dtsch Med Wochenschr 1993; 118: 765.
4. BUCK AC, COOKE EM. The fate of ingested Pseudomonas aeruginosa in normal persons. J Med Microbiol 1969; 2: 521-525.
5. CESARO S, CHINELLO P, ROSSI L, ZANESCO L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8: 504-505.
6. COLE GT, HALAWA AA, ANAISSIE EJ. The role of gastrointestinal tract in hematogenous candidiasis from the laboratory to the bedside. Clin Infect Dis 1996; 22 (Suppl): 73S-88S.
7. D'SOUZA AL, RAJKUMAR CH, COOKE J, BULPITT CHJ. Probiotics in prevention of antibiotic associated diarrhoe: meta-analysis. BMJ 2002; 324: 1361-1366.
8. EBRINGER L, FERENČÍK M, LAHITOVÁ N, KAČÁNI L, MICHÁLKOVÁ D. Antimutagenic and imunostimulatory properties of lactic acid bacteria. World J Microbiol Biotechnol 1995; 11: 294-298.
9. EKERK H, JURK IH, WATERS KD, TIEDEMANN K. Prophylactic co-trimoxazole and lactobacilli preparation in neutropenic patients. Med Pediatr Oncol 1980; 8: 47-51.
10. ELMER GW, SURAWICZ CM, McFARLAND LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 2002; 275: 870-876.
11. ENGELS AE, LAU J, BARZA M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
12. FERENČÍK M, EBRINGER L, MIKEŠ Z, JAHNOVÁ E, ČIZNÁR I. Beneficial modification of the human intestinal microflora using orally administered lactic acid bacteria. Bratisl Lek Listy 1999; 100: 238-245.
13. FRUCHART C, SALAH A, GRAY C, MARTIN E, STAMATOULLAS A et al. Lactobacillus species as emerging pathogens in neutropenic patients. Eur Clin Microbiol Infect Dis 1997; 16: 681-684.
14. FULLER R. Probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-378.
15. GASSER S. Safety of lactic acid bacteria and their occurence in human clinical infection. Bull Inst Pasteur 1994; 92: 45-67.
16. GORBACH SL, BARZA M, GIULIANO M, JACOBUS NV. Colonization resistance of the human intestinal microflora: testing the hypothesis in normal volunteers. Eur J Clin Microbiol Infect Dis 1988; 7: 98-102.
17. HASEGAWA T, KANASUGU H, HIDAKA M, YAMAMOTO T, ABE S, YAMAGUCHI H. Effect of orally administered heat-killed Enterococcus faecalis FK-23 preparation on neutropenia in dogs treated with cyclophosphamide. Int Immunopharmacol 1996; 18: 103-112.
18. HAVENAAR R, SPANHAAK S. Probiotics from an immunological point of view. Curr Opin Biotechnol 1994; 5: 320-325.
19. HENGENS C, KLASTERSKY J. Intestinal colonization with lactobacilli strains in neutropenic patients. Biomedicine 1976; 25: 11-15.
20. HUYCKE MM, SAHM DF, GILMORE MS. Multiple drug resistant enterococci: The nature of the problem and an agenda for the future. Emerging Infectious Diseases 1998; 4: 239-249.
21. ISOLAURI E, JUNTUNEN M, RAUTANEN T, SILLANAUKEE P, KOIVULA T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90-97.
22. KLASTERSKY J. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients. Diagn Microbiol Infect Dis 1989; 12 Suppl 4: 201S-207S
23. LEONARD F, ANDREMONT A, LECLERQ B, LABIA R, TANCREDE C. Use of B-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J Infect Dis 1989; 160: 274-280.
24. MARIN ML, TEJADA-SIMON MV, LEE JH, MURTHA J, USTUNOL Z, PESTKA JJ. Stimulation of cytokine production in clonal macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus. J Food Prot 1998; 61: 859-864.
25. MARSHALL JC. Gastrointestinal flora and its alterations in critical illness. Curr Opin Clin Nutr Metab Care 1999; 2: 405-411.
26. McFARLAND LV, SURAWICZ CM, GREENBERG RN, FEKETY R, ELMER GW et al. A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994; 271: 1913-1918.
27. MIKEŠ Z, FERENČIK M, JAHNOVÁ E, EBRINGER L, ČIZNÁR I. Hypocholesterolemic and immunomodulaory effects of orally applied Enterococcus faecium M-74 in man. Folia Microbiol 1995; 40: 639-646.
28. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
29. NAUSEEF WM, MAKI DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304: 448-453.
30. NEUMANN E, OLIVEIRA MA, CABRAL CM, MOURA LN, NICOLI JR et al. Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germ free mice. Braz J Med Biol Res 1998; 31: 1565-1573.
31. PERDIGON G, ALVAREZ S, RACHID M, AGUERO G, GOBBATO N. Immune system stimulation by probiotics. J. Dairy Sci 1995; 78: 1597-1606.
32. REID G, BRUCE AW. Urogenital infections in women: can probiotics help? Postgrad Med J 2003; 79: 428-432.
33. RESTA-LENERT S, BARRETT KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherischia coli (EIEC). Gut 2003; 52: 988-997.
34. RICHARD V, VAN DER AUWERA P, SNOECK R, DANEAU D, MEUNIER F. Nosocomial bacteriemia caused by Bacillus species. Eur J Microbiol Infect Dis 1998; 7: 783-785.
35. RIQUELME AJ, CALVO MA, GUZMAN AM, DEPIX MS, GARCIA P et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41-43.
36. SAINT-MARC T, ROSSELLO-PRATS L, TOURAINE JL. Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS (letter). Ann Med Intern 1991; 142: 64-65.
37. SATONAKA K, OHASHI K, NOHMI T, YAMAMOTO T, ABE S et al. Prophylactic effect of Enterococcus faecalis FK-23 preparation on experimental candidiasis in mice. Microbiol Immunol 1996; 40: 217-222.
38. SIMON GL, GORBACH SL. Intestinal microflora in health and disease. Gastroenterology 1984; 86: 174-193.
39. SCHIMPFF SC, YOUNG VM, GREEN WH. Origin of infection in acute lymphocytic leukemia: significance of hospital aquisition of potential pathogens. Ann Intern Med 1972; 77: 707-714.
40. TAGUCHI H, TAKAHASHI M, YAMAGUCHI H et al. Experimental infection of germ-free mice with hyper-toxigenic enterohemorrhagic Escherischia coli O157:H7, strain 6. J Med Microbiol 2002; 51: 336-343.
41. VANDENPLAS Y. Bacteria and yeast in the treatment of acuta and chronic infectious diarrhea. Part I. Bacteria. Clin Microbiol Infect 1999; 5: 299-307.